Commentary on: Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Aesthetic surgery journal
Oxford University Press
MetadataShow full item record
Turner, S., & Wright, P. (2020). Commentary on: Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma.. Aesthetic surgery journal, 40 (2), 154-155. https://doi.org/10.1093/asj/sjz025
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon and emerging entity. It is a T-cell lymphoma that is usually localised within a late-onset peri-implant seroma that develops, on average, at 10 years after implant placement. In those cases limited to the seroma fluid, treatment in the form of complete capsulectomy by surgical excision may be curative1. However, for some patients, disease presents as a solid mass extending beyond the implant capsule and/or involving lymph nodes. These patients, in addition to surgery, require conventional chemotherapy and the antibody-drug conjugate brentuximab vedotin, which selectively targets tumor cells expressing the CD30 antigen has been shown to have superior activity in some cases2,3.
Humans, Breast Neoplasms, Breast Implantation, Breast Implants, Lymphoma, Large-Cell, Anaplastic, Ki-1 Antigen
External DOI: https://doi.org/10.1093/asj/sjz025
This record's URL: https://www.repository.cam.ac.uk/handle/1810/289051